Stockreport

Replay wins IND clearance for PRAME T cell cancer therapy [Yahoo! Finance]

Immunocore Holdings plc - American Depositary Shares  (IMCR) 
PDF PRAME TCR/IL-15 NK (SY-307) is an engineered T cell receptor natural killer (TCR-NK) cell therapy, targeting preferentially expressed antigens in melanoma (PRAME). The [Read more]